ALERCE MEDICAL TECHNOLOGY PARTNERS
ALERCE MEDICAL TECHNOLOGY PARTNERS
Status:
Active
Similar Organizations
Cercano Management
Cercano Management is an investment firm.
Finality Capital Partners
Finality Capital Partners is an investment firm.
Huobi Ventures
Huobi Ventures is an investment firm.
Mirana
Mirana is an investment firm.
Road Capital
Road Capital is an investment firm.
Spring Point Partners
Spring Point Partners is an investment firm.
Starshot Capital
Starshot Capital is an investment firm.
Techmine
Techmine is an Investment firm.
Yidashu Biotechnology
Yidashu Biotechnology is an Investment firm.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-06-12 | Alzheon | Alerce Medical Technology Partners investment in Series E - Alzheon | 100 M USD |
| 2022-09-22 | Aadi Bioscience | Alerce Medical Technology Partners investment in Post-IPO Equity - Aadi Bioscience | 72.5 M USD |
More informations about "Alerce Medical Technology Partners"
Alerce Medical Technology Partners - Crunchbase
Alerce Medical Technology Partners is an Investment firm. Lists Featuring This Company. Edit Lists Featuring This Company Section ... 9,922 Number of Organizations • $676.5B Total …See details»
Alzheimer's Drug Developer Alzheon Closes $100M …
Jun 12, 2024 Alerce Medical Technology Partners led the group of investors that raised the Series E round. None of those other investors were disclosed in Alzheon’s announcement of the financing.See details»
Alerce Medical Technology Partners - Crunchbase
Jun 12, 2024 Alerce Medical Technology Partners is an Investment firm. Aadi Bioscience Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology …See details»
Alzheon Secures $100M Series E for ALZ-801 Alzheimer's Treatment
Jun 17, 2024 The financing round was led by Alerce Medical Technology Partners, complementing a previous $50 million raised in Series D in 2022. Founder, President, and …See details»
Alzheon Raises $100 Million Series E Financing Round to
Jun 12, 2024 Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s …See details»
Alzheon secures $100m to advance Alzheimer’s disease …
Jun 13, 2024 Alerce Medical Technology Partners spearheaded the financing round. Go deeper with GlobalData. Reports. LOA and PTSR Model - ACU-193 in Alzheimer's Disease . ... the last two financing rounds in the current climate …See details»
Series E - Alzheon - 2024-06-12 - Crunchbase Funding Round Profile
Jun 12, 2024 Organization Name . Alzheon . Announced Date Jun 12, 2024; Funding Type Series E; Funding Stage Late Stage ... Edit Lead Investors Section. Alerce Medical …See details»
Alzheon: $100 Million Closed To Advance …
Jun 19, 2024 Alzheon, a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, announced …See details»
Alzheon Raises $100 Million Series E Financing Round …
Jun 12, 2024 Our ability to raise $150 million over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology," said Martin Tolar, MD, PhD ...See details»
Alzheon raises $100m for Alzheimer's treatment
Jun 17, 2024 Alzheon, a clinical-stage biopharmaceutical company, has successfully raised $100 million in a Series E funding round.This investment will be pivotal for the development …See details»
Venture Report: Clinical plays Alzheon, Bright Peak raise growth …
Jun 14, 2024 The deal, led by Alerce Medical Technology Partners, provides Massachusetts-based Alzheon Inc. with the capital necessary to complete the Phase III APOLLOE4 study of …See details»
Alzheon lands $100m to advance oral Alzheimer’s drug towards ...
Jun 13, 2024 The funding round, which was led by Alerce Medical Technology Partners, follows a $50 million Series D round completed in 2022. “At Alerce, we focus on investing in …See details»
With fresh $100M, Alzheon lays out strategy for Alzheimer’s …
Jun 12, 2024 The round, led by Alerce Medical Technology Partners, brings Alzheon’s total equity financing to $185 million. The pivotal trial is expected to read out in the third quarter, …See details»
Alzheimer’s Drug Developer Alzheon Closes $100M Series E …
Jun 12, 2024 Alerce Medical Technology Partners led the group of investors that raised the Series E round. None of those other investors were disclosed in Alzheon’s announcement of …See details»
Alzheon plans Alzheimer's approval next year with new $100M
The funding, led by Alerce Medical Technology Partners, raises Alzheon’s total equity financing to $185 million. The pivotal trial results are anticipated in the third quarter, with a regulatory …See details»
Board of Directors - WoodBridge Healthcare
Throughout his career, he has led a diverse range of hospitals, from a 74-bed rural facility to a major 300-plus-bed organization. Most recently, he served as the President and CEO of Plaza …See details»
Woodbridge International Closes Sale of Alternative Exports, Inc.
Jun 30, 2021 Woodbridge International, a global mergers and acquisitions firm, is pleased to announce the acquisition of its client, Alternative Exports Inc., by 3T Medical Systems and …See details»
Top Medical Device Executive Recruiters - JRG Partners LLC
JRG Partners is a trusted medical device executive placement agency, connecting top talent with leading companies. Let us help you find the right leaders for your organization. Skip to content …See details»
Executive Leadership Team - Southlake Health
A registered Medical Radiation Technologist (MRT), Amir holds a Bachelor’s degree in Radiation Sciences and Nuclear Medicine Technology; and a Masters degree in Executive Leadership. …See details»
Alzheon Raises $100 Million Series E Financing Round to Advance ...
Jun 13, 2024 “At Alerce, we focus on investing in companies in the late stages of development that are developing lifesaving drugs or devices with the potential to benefit millions of patient …See details»